Condition: Esophageal Cancer · Chemoradiotherapy · Albumin-bound Paxlitaxel · Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
This phase I/II clinical study is designed to evaluate the 1 year local tumor control rate of chemoradiotherapy using albumin-bound paclitaxel and cisplatin in unresectable esophageal squamous cell carcinomas based on Nutritional Risk Screening NRS2002.
This description comes directly from the study's public registry record.
Xin Wang, MD · +861013311583220 · beryl_wx2000@163.com
Always discuss trial participation with your own doctor first.
| Department 4th of Radiation Oncology, Anyang Cancer Hospital | Anyang, Henan, China | Recruiting |
| Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University | Changsha, Hunan, China | Recruiting |
| Department of Radiation oncology, Jiangsu Cancer Hospital/Jiangsu Institute of Cancer Research/The affiliated Cancer Hospital of Nanjing Medical University | Nanjing, Jiangsu, China | Recruiting |
| Department of Radiation oncology, Jiangsu Province Hospital/The First Affiliated Hospital with Nanjing Medical University | Nanjing, Jiangsu, China | Recruiting |
| Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04278287